Evotix on Mission to Reduce Workplace Accidents in Europe and USA
2.11.2021 12:00:00 EET | Business Wire | Press release
Every year over 5,000 people are killed in workplace accidents in the US and EU – a number that’s risen in the US over the last ten years1 - and blue-collar workers in the US are five times as likely to have accidents as their white-collar counterparts2.
Evotix, an ESG business, formerly known as SHE Software and a world leader in environmental, health, safety and well-being software (EHS), announces today its mission to help organizations reduce these numbers through its investment in new staff, software, support and training services.
The business’ proposition is focussed on giving its clients ‘the confidence to transform’. For many organizations, changing the way they handle health and safety can be daunting because they don’t want to uproot established practices even if they are based on out-of-date processes and technologies. Evotix has the in-depth expertise in the latest technologies, especially those that improve and simplify the user experience, that enables organizations to implement the changes they – and their employees – need to make EHS simpler and safer.
Matthew Elson, CEO of Evotix, explains, “People, especially those that are less advantaged, have the right to work in a safer environment. Our business already helps protect the safety of over 3,000,000 employees worldwide and we’re determined to protect many, many more in the years to come.”
“Too many employees suffer workplace accidents or endure workplace related physical and mental health problems, causing issues not only for those individuals but for businesses and wider society. Many of these unfortunate situations would be avoidable if health and safety were embedded in the way the organization truly functions, supported by software featuring the latest user-friendly technologies. Engaging employees on safety issues needs to be simple, sustainable and tailored for the need of each individual organization and that’s what Evotix has been built to offer.”
“The introduction of the Evotix name is just one step on our journey. The SHE Software name has served us well during our early years, but we wanted a name that was both memorable and reflects our vision and evolved proposition. The Evotix name is a conflation of the key qualities that make us special – evolutionary technology, innovation and experience.”
Based in Chicago and London, over the past five years Evotix has grown by over 40% every year and now has over 130 staff across the US, Europe and Asia-Pacific. In the last two years the company has experienced its fastest ever growth and major customers include: GlaxoSmithKline, New Balance, Citrix and University of Cambridge.
SOLUTIONS FOR TOMORROW
Evotix focusses on promoting workplace health and safety by providing innovative and engaging technology that gets embedded in the everyday flow of activity.
Evotix provides a comprehensive solution covering all aspects of health and safety management.
The solution is online and mobile-first designed to be used quickly and easily on-the-spot. With Evotix, incidents can be reported and shared within minutes, actions can be tracked to completion and underlying trends can be analysed.
Understanding documents on a mobile phone can be challenging: many organizations have a percentage of their workforce who are illiterate. Evotix employs microlearning video and quizzes in the field to engage employees in understanding risk and following defined working methods.
Every organization is different so the software can be easily tailored and adapted as requirements evolve. Evotix is continually adding new innovation as technology evolves.
Matthew continues, “Our approach helps organizations and employees alike. For organizations, accidents and incidents are expensive, with direct costs including lost hours, damage, disruption and claims, and indirect costs including the impact on morale, reputation, stress and management distraction. “
“We believe employees deserve better. The risks associated with workplace accidents fall disproportionately on the most disadvantaged in society - gig economy workers, casual labourers. An organization that prioritises risk reduction for all its staff will perform better financially, operationally and reputationally. That’s where we are here to help.”
Dawn Hemmings at Citrix says, “I’ve partnered with Evotix for over five years at three different organisations. I have always valued them as a partner that cares as passionately about improving workplace safety as I do. That’s why, when I joined Citrix, one of my first actions was to call Evotix. We know that their vision to make EHS simpler, more intuitive and more engaging is aligned with ours and they have the capabilities and plans to make that vision a reality.”
ABOUT EVOTIX
Evotix is a global ESG technology company transforming the way employees engage in workplace health and safety. Its market leading solution, Assure, is used by more than 400 customers across a wide range of industries including manufacturing, food & drink, construction, utility services, transport & logistics, municipalities, healthcare, education and housing.
Customers include GlaxoSmithKline, New Balance, Citrix, Finsbury Foods, Eddie Stobart, Network Rail, Wacker Neuson, Euro Car Parts and University of Cambridge.
Evotix’s intuitive, mobile first application fosters worker participation, guiding frontline activities while capturing rich data to help prioritise safety and operational improvements and ensure compliance. Ease of deployment and resulting swift customer impact drive Evotix’s rapid multi-year growth.
Evotix has offices in Chicago, London, Manchester, Glasgow and Melbourne, and is backed by significant investors including Mercia Asset Management and Frog Capital.
1 Eurostat: Accidents at work; US Bureau of Labor Statistics: Fatal occupational injuries
2 US Bureau of Labor Statistics: Fatal occupational injuries
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211102005108/en/
Contact information
Giles Fraser at Brands2Life
+44 207 592 1200
info@brands2life.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Teledyne FLIR Defense Wins $17.5 Million Contract from armasuisse to Deliver Black Hornet 4 Nano-Drones for Dismounted and Vehicle-Integrated Reconnaissance2.2.2026 09:00:00 EET | Press release
Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE:TDY), announced that it has received a $17.5 million contract from armasuisse, the Swiss Federal Office of Defence Procurement, to deliver a large number of Black Hornet® 4 Personal Reconnaissance Systems, one of the world’s most advanced and widely deployed nano-drones. Black Hornet 4 was selected as an airborne dismountable Intelligence, Surveillance, and Reconnaissance (ISR) capability sensor for armasuisse’s Piranha 8x8 Armored engineering vehicle program. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260201061637/en/ Teledyne FLIR Defense has won a $17.5 million contract from armasuisse, the Swiss Federal Office of Defence Procurement, to deliver a large number of Black Hornet® 4 Personal Reconnaissance Systems, one of the world’s most advanced and widely deployed nano-drones. Black Hornet 4 was selected as an airborne capability sensor for armasui
Galderma Announces U.S. FDA Acceptance of RelabotulinumtoxinA Biologics License Application Resubmission2.2.2026 08:00:00 EET | Press release
Galderma (SIX: GALD) today announced that the U.S. FDA has accepted the BLA resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet) in adults. Galderma has worked closely with the U.S. FDA to implement adjustments to its manufacturing process. Galderma is committed to using its expertise and heritage in the neuromodulator space to develop next-generation aesthetic solutions that address evolving needs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260201157212/en/ “We pioneered the development of RelabotulinumtoxinA to address the growing demand for faster-acting and longer-lasting anti-wrinkle solutions. We’re excited about the potential to bring this innovative neuromodulator to the U.S., offering advanced performance and ease of use and building on our portfolio of neuromodulators that meets the full spectrum of injecto
High-end Aesthetic Brand ‘Lorient’ Gains Global Prestige at IMCAS 20261.2.2026 09:00:00 EET | Press release
Lorient, a premium aesthetic brand, announced that it has drawn global attention at the 27th IMCAS World Congress 2026 in Paris, attracting over 15,000 professionals and demonstrating its leadership in aesthetic innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131322203/en/ Lorient’s low degree of modification delivers a smooth injection experience and high biocompatibility (Image: Lorient) The highlight was a session led by Dr. Jani van Loghem, a globally revered key opinion leader known for establishing international aesthetic safety protocols. His involvement provided a prestigious validation of the technical excellence of Lorient. Alongside him, prominent Korean medical experts Dr. Won Lee and Dr. Do Young Rhee shared clinical insights that drew widespread praise from the international medical community. Central to the academic discussions was Lorient’s "safety-first" philosophy for its premium HA filler ran
Sharjah Ruler Receives Portugal’s Grand Collar of Order of Camões31.1.2026 19:27:00 EET | Press release
His Excellency Marcelo Rebelo de Sousa, President of the Portuguese Republic, awarded His Highness Sheikh Dr Sultan bin Mohammed Al Qasimi, Supreme Council Member and Ruler of Sharjah, the Grand Collar of the Order of Camões (Grande Colar da Ordem de Camões), the highest sovereign cultural order in Portugal. His Highness is the first Arab figure to receive the Order of Camões and the sixth recipient worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131119526/en/ Sharjah Ruler receives Portugal’s Grand Collar of Order of Camões (Photo: AETOSWire) The honour was conferred during a ceremony hosted by the Portuguese President at the Presidential Palace in Lisbon. The event was attended by Sheikha Bodour bint Sultan Al Qasimi, Chairperson of the Sharjah Book Authority, alongside senior officials. The ceremony recognised His Highness’s prominent global stature, as a leading figure in culture, intellectual thought and in
Incyte Announces Positive CHMP Opinion for Zynyz ® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 16:29:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “Today’s positive CHMP opinion is an important step towards addressing the urgent need for new treatment options for patients in Europe with advanced SCAC, a disease which has seen limited innovation for decades,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved, Zynyz in combination with platinum-based chemotherapy has the potential to become a new standard-of-care for patients living with this rare and difficult-to-treat cancer.” The positive CHMP opinion was based on data from the Phase 3 POD1UM-303/Inter
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
